Merck & Co. Short Interest Up 13.9% in June (MRK)
Merck & Co. (NYSE:MRK) saw a large increase in short interest during the month of June. As of June 13th, there was short interest totalling 33,266,511 shares, an increase of 13.9% from the May 30th total of 29,199,196 shares, StockRatingsNetwork reports. Currently, 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 8,013,666 shares, the short-interest ratio is currently 4.2 days.
In other Merck & Co. news, Insider Willie A. Deese unloaded 72,290 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $58.26, for a total transaction of $4,211,615.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on MRK. Analysts at Barclays raised their price target on shares of Merck & Co. from $50.00 to $61.00 in a research note on Wednesday, July 2nd. They now have an “equal weight” rating on the stock. Separately, analysts at Bank of America reiterated a “buy” rating on shares of Merck & Co. in a research note on Thursday, June 12th. They now have a $62.00 price target on the stock, down previously from $65.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co. in a research note on Tuesday, May 20th. They now have a $59.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $60.23.
Shares of Merck & Co. (NYSE:MRK) opened at 59.20 on Monday. Merck & Co. has a 52 week low of $44.62 and a 52 week high of $59.84. The stock has a 50-day moving average of $57.76 and a 200-day moving average of $55.29. The company has a market cap of $173.0 billion and a price-to-earnings ratio of 38.95.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.79 by $0.09. The company had revenue of $10.30 billion for the quarter, compared to the consensus estimate of $10.44 billion. During the same quarter in the prior year, the company posted $0.85 earnings per share. The company’s quarterly revenue was down 3.8% on a year-over-year basis. On average, analysts predict that Merck & Co. will post $3.47 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, July 8th. Investors of record on Monday, June 16th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a dividend yield of 2.97%. The ex-dividend date is Thursday, June 12th.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.